Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Announces Planned Survey Of Current Cosmetics Manufacturing Practices

This article is powered by The Rose Sheet

Executive Summary

The agency expects 70% of invited manufacturers to provide voluntary detail on their written procedures and records maintenance, equipment and raw materials management, product testing programs, processes for handling complaints and corrective action pathways, among other elements, via a 30-minute survey. Comments on the planned initiative will be accepted through August.

You may also be interested in...



FDA Targets Spring 2019 For Cosmetics Manufacturing Survey; PCPC Input Taken

From the Personal Care Products Council’s standpoint, FDA’s planned survey of current manufacturing practices in the cosmetics sector isn’t necessary, but the group provided input to contractor RTI to help develop the instrument for optimal utility. Pending OMB approval, FDA aims to launch the survey in spring 2019.

FDA: Anonymity Assured In Pending Cosmetic Manufacturing Practices Survey

The agency clarified in an email to Rose Sheet that an independent contractor would be tasked with conducting a planned survey on current cosmetic manufacturing practices, which remains subject to public comment and OMB approval. Respondents could count on their responses to be anonymous, FDA says.

FDA Streamlining Voluntary Cosmetic Registration, With Participation On The Rise

New accounts are up 156% from 2014 in FDA’s Voluntary Cosmetic Registration Program, according to FDA, which has made improvements to streamline the submission process for participants and lighten the load on agency staffers. Further changes recommended by industry are currently under consideration.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121693

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel